DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

Information source: University of Nebraska
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Non-hodgkin's Lymphoma; Mantle Cell Lymphoma

Intervention: Bortezomib (Drug); BEAM (Drug); autologous peripheral blood stem cell transplantation (Procedure)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: University of Nebraska

Official(s) and/or principal investigator(s):
Julie M Vose, M.D., Study Chair, Affiliation: University of Nebraska

Summary

This is a Phase I/II trial designed to study the toxicity and Maximum Tolerated Dose of VELCADE in combination with BEAM and autologous hematopoietic stem cell transplantation and to obtain a preliminary estimate of the response rate to this combination.

Clinical Details

Official title: Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Maximum Tolerated Dose

Secondary outcome:

Response rate

overall survival

event-free survival

Detailed description: Primary Objective: To evaluate in a phase I study the toxicity and MTD of the addition of VELCADEâ„¢ (bortezomib) to a standard BEAM autologous transplant regimen. The phase II portion of the study will determine a preliminary estimate of the response rate. Secondary Objectives: To obtain a preliminary estimate of the response rate to this regimen. To obtain preliminary estimates of event-free and overall survival using this regimen. Enrolled subjects will receive Velcade in combination with BEAM and Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Phase I treatment will administer Velcade in four dose cohorts,in addition to the BEAM and AHSCT. Three patients will be accrued in each dose cohort with enrollment starting at dose cohort. These subjects will be evaluated to establish the maximum tolerated dose of Velcade in combination with BEAM autologous peripheral blood stem cell transplantation. Once established, the maximum tolerated dose will be utilized in treating an additional 20 subjects. Follow-Up: Data collected will be utilized to obtain a preliminary estimate of the response rate, event-free and overall survival using this regimen.

Eligibility

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Persistent, relapsed or refractory indolent non-Hodgkin's lymphoma (Follicular grade

I, II, or III), non-Hodgkin's lymphoma, composite lymphomas with ≥ 50% of tumor showing follicular histology, transformed follicular, lymphoplasmacytic, marginal zone lymphoma, small Lymphocytic Lymphoma (including T-cell subtypes), or mantle cell lymphoma that is relapsed, refractory, or in PR1 or CR1 (MCL only for CR1).

- Age >19 years.

- Signed written informed consent.

- Expected survival duration of > six months.

- Karnofsky Performance Status > 70.

- Eligible patients must have: Liver functions < 3x upper limits of normal (ULN)

unless due to disease; ANC > 500 cells/mm3 and Platelet Count > 50 mm3.

- Patients > age 60 or with clinical signs of heart disease must have ejection fraction

≥ 45% LVEF.

- Patients with clinical signs of pulmonary insufficiency must have DLCO to be measured

at > 50% of predicted value.

- Able to collect > 1. 2 X 106/kg CD34+ cell for transplantation.

- No serious disease or condition that, in the opinion of the investigator, would

compromise the patient's ability to participate in the study.

- Female patients must not be pregnant or lactating.

- Male and female patients of reproductive potential must follow accepted birth control

measures. Exclusion Criteria:

- Patients who are HIV seropositive

- Serum creatinine >2. 5mg/dL or calculated creatinine clearance ≤ 50ml/min

- Total bilirubin >3 times upper limits of normal (unless due to Gilberts disease or

malignancy), ALT and AST >4 times the upper limits of normal

- Active infection at the time of transplant

- Myocardial infarction within 6 months prior to enrollment or has New York Hospital

Association (NYHA) Class III or IV heart failure uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.

- Patient has hypersensitivity to bortezomib, boron or mannitol.

- Female subject is pregnant or breast-feeding. Confirmation that the subject is not

pregnant must be established by a negative serum pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.

Locations and Contacts

University of Nebraska Medical Center, Section of Oncology/Hematology, Omaha, Nebraska 68198-7680, United States
Additional Information

Starting date: April 2006
Last updated: August 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017